Reviewing Axovant Sciences (AXON) & The Competition
Axovant Sciences (NASDAQ: AXON) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Axovant Sciences to related companies based on the strength of its analyst recommendations, risk, profitability, earnings, valuation, dividends and institutional ownership.
Earnings & Valuation
This table compares Axovant Sciences and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Axovant Sciences||N/A||-$180.95 million||-2.18|
|Axovant Sciences Competitors||$284.28 million||$34.29 million||133.51|
This table compares Axovant Sciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axovant Sciences Competitors||-5,349.08%||-434.35%||-39.98%|
This is a breakdown of current recommendations for Axovant Sciences and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axovant Sciences Competitors||848||3199||11599||230||2.71|
Axovant Sciences currently has a consensus price target of $14.68, indicating a potential upside of 192.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.24%. Given Axovant Sciences’ higher possible upside, research analysts plainly believe Axovant Sciences is more favorable than its competitors.
Insider & Institutional Ownership
96.9% of Axovant Sciences shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 72.4% of Axovant Sciences shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Axovant Sciences has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Axovant Sciences’ competitors have a beta of 5.63, indicating that their average stock price is 463% more volatile than the S&P 500.
Axovant Sciences competitors beat Axovant Sciences on 7 of the 12 factors compared.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.
Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.